Sign in

    Anthony Polak

    Research Analyst at Aegis Capital Corporation

    Anthony Polak is the Managing Director of Wealth Management at Aegis Capital Corporation, advising high-net-worth clients with a specialization in comprehensive wealth management. He has a longstanding career in the financial sector and is recognized for his prudent investment strategies benefitting a broad client base; however, detailed public information on his performance metrics and specific company coverage is limited. Polak began his professional journey after earning a Bachelor of Arts and an MBA from American University, bringing over two decades of experience to his role at Aegis Capital. He is FINRA-registered and holds requisite securities licenses, demonstrating a commitment to regulatory standards and ethical client service.

    Anthony Polak's questions to BALCHEM (BCPC) leadership

    Anthony Polak's questions to BALCHEM (BCPC) leadership • Q2 2025

    Question

    Anthony Polak of Aegis Capital Corporation questioned the potential impact of U.S. tariffs on the company and requested an update on the CureMark partnership.

    Answer

    Chairman, President & CEO Ted Harris addressed the questions, stating that the estimated impact from tariffs has risen to approximately $25 million, but the company remains confident it can offset this through supply chain shifts and pricing actions. Regarding CureMark, he reported no significant new developments, as the next step is for CureMark to file the BLA with the FDA. Balchem has completed all its necessary manufacturing and validation preparations.

    Ask Fintool Equity Research AI